Bulls 2011

CYDY / Message Board / Read Message BOARD GROUPS return to message board, top of board Msg 222 of 224 at 2/28/2020 10:49:26 PM by rubraquercus In response to msg 220 by rubraquercus view thread Hi All- I wanted to share this break through stock with everyone. They have a drug called Leronlimab that is only to change the HIV and Cancer landscape IMO. Please read below. Their drug is in BTD (Biological Therapeutic Designation) for HIV, which was fast tracked through the FDA right now. The FDA granted them a basket trial for 22 different forms of tumorous cancer as of a week ago. It is being tested in China right now for the Corona Virus. This stock could be the opportunity of a lifetime. Please read below. Re: CYDY article Leronlimab (Pro 140) Cliff Notes What is it? Leronlimab is a humanized monoclonal antibody targeted against the CCR5 receptor expressed on sub-population of T cells, macrophages, dendritic, eosinophils, microglia, and several cancers types. Why so many indications? CCR5 is a chemokine receptor interacting with CCL3, CCL4, and CCL5 (RANTES). CCL5 has an active role in recruiting leukocytes into inflammatory sites, which leronlimab can block. CCR5 also has many other roles: [8,9] - governing DNA damage repair, - repolarization of tumor-associated macrophages, - promoting leukocytes (and metastatic cancer ccr5+ cells) trafficking to the brain, bones, liver and lungs. What makes it to stand out from than other ccr5 antagonists, HAART, and cancer drugs ? Low toxicity: Doesn't block natural activity of ccr5 including no hepatotoxicity causing many others to fail their trial safety metric. No R5 resistance: Competitive inhibitor blocking direct entry to target a specific site on CCR5 that is utilized by HIV vs allosteric in small molecule, which enables resistance development in all small molecule antagonists. With the highest barrier to resistance so far than any other HIV drug, it could be first monotherapy approved drug for HIV. Weekly dosing/Adherence : Longer half-life (10-14 days) [11,12] allows weekly dosing vs daily pills with others. A large 2013 survey [6,7] of 19 studies showed the association between adherence and specific AEs associated with ART. The same study showed an association with adherence rate and the number of daily pills, 95% adherence from 47% taking one pill daily to 34% with three pills daily. NNRTI, which has traditionally been given as part of core with ART, needs a very high level of adherence to limit mutations Adherence is the second strongest predictor of progression to AIDS after CD4 count. Weekly dosing offers a tremendous advantage in increasing adherence, specifically those in the unmet need category where typically adherence has been the lowest. Note PrEP study will have one arm with monthly dosing as daily pills is one main reason people at risk have stated they avoided PrEP, longer options are better. Safety: No serious side effects or serious adverse events in over 830 patients. No discontinuing thus far from AEs in mono p2 trial. This makes leronlimab unique among many HIV and cancer drugs. Recognizing overall's drug’s safety FDA has allowed P1 to be skipped in several new indications. This is also helps reduce the added compounding side-effects when using several drugs with HIV or cancer. Low drug/drug interactions. Leronlimab is eliminated via a saturable, antigen-mediated clearance process [10]. Many other HIV drugs are metabolized by CYP enzymes enabling drug interactions. For example Maraviroc and Rilpivirine are metabolized by CYP3A4, as are many other drugs. Special Note: HIV has a positive association with NAFLD and cancer, two indications where leronlimab is in p2, which combined with the above benefits, if approved for all indications would make a extremely compelling synergistic treatment for all R5. See end footnote for more details. Video: Pro 140: How it Combats HIV Science Advisors : Dr Sacha/OHSU, Dr. Patterson/IncellDx, Dr. Lindner/ Cleveland Clinic, Dr. Dennis Burger/ex-CSO CYDY, also CEO of several nasdaq bio, Dr. Maddon (inventor or leronlimab and discovered CD4/HIV connection) Clinical Advisors : Dr Dhody/Amarex Clinical Research, Dr Dolezal/Pacific Hematoloty, Dr. Lalezari/Quest Clinical Research Manufacturing : AGC & Samsung Biologics (mAb global leader which approved deal with no upfront payment) HIV: Combo: Unmet Need R5 Population. Fast Track Designation, Completed Phase3 with BLA submission December/January, BLA rolling review Mono: R5 Population suppressed V.: In Phase 2b/3 investigatory trial. Phase 3 pivotal could start 2020 with FDA approval, 5 patients on mono five years with no drug resistance; over 150 patients on mono for over 1 year PrEP: Coordinating with Thai Red Cross/Dr Sacha funding for 1200 patient study, one arm monthly dosing Potential partner US Army, talks with US Senators with funding, first goal BTD submission. Though an estimated 70% of HIV population is R5, over 90% of HIV sexual transmissions occur throuh the CCR5 pathway. [5] Licensing: Vyera US/HIV only, 50% net sales & 87M milestone. Other global and US non-HIV still open. FDA denied ODD stating population larger than 200k is a possibility Cancer Animal: 98% metastatic tumor burden reduction in tnbc mice model mTNBC — Fast Track Designation: Phase 1b/2: Patient 1 CTC reduced to zero in first eight weeks, matching similar results in animal model. Enrolling next two soon. Will Apply for BTD if similar results Colon —Phase 2 approval, 30 patient with Regorafenib, enrollment not started Compassionate use approved: melanoma, pancreatic, lung, liver, breast, and prostate Basket trial with in works with melanoma, pancreatic, lung, liver, breast, and prostate NASH Animal: inhibited lipid uptake, liver fibrosis, and fatty liver development Phase 2 approval, 60 patients, random, double blind-enrollment not started Brenden Rae, “ we expect there to be a significant interest from industry stakeholders in the development of leronlimab for the treatment of NASH.” GvHD : Orphan Drug Designation Animal: 100% survival with leronlimab vs 0 without Phase 2 approval 60 patient, enrollment not started Note: P2 maraviroc trial with GvHD successful Multiple Sclerosis P2 protocol already finalized by Dr. Denis Burger following same structure of Biogen's Tysabri. IND submission early 2020 History In 1994, Stephen Crohn [2] became the first person observed to have some genetic resistance to HIV, he had mutation later known as ccr5-delta-32. Ths mutation has been used to aid two 'sterilizing' cures known to date with using a high-risk delta 32 stem cell transplantation to treat life-treating leukemia and Hodgkin's lymphoma respectively for Timothy Brown original referred to as the Berlin Patient (2007) and London Patient (2019). Progenics, founded by Paul Maddon in 1986, originally developed leronlimab. Their scientist and collaborators on the original team that in 1996 discovered CCR5 is necessary as a co-receptor for entry macrophage tropic HIV in strains now called R5[1]. In 1999, from 10,000 hybridoma supernatants screened, and over 100 inhibiting ccr5, seven were selected for testing [3]. From those seven, leronlimab was selected partly due to its wide coverage in all tested R5 strains and the observation that it does not antagonize natural receptor activity [4], which gives low treatment-related toxicities compared to other ccr5 antagonist or highly-active antiretroviral therapy used in HIV. At Progenics, leronlimab, entered phase 1 in 2006 followed by two phase 2 studies in 2008, one IV and the other subcutaneous for HIV R5 strain with results published in 2010. Progenics switched focus in 2010 to other potential drugs in their pipeline, partly influenced by the FDA pathway given of leronlimab through unmet need estimated taking many years. In 2012, CytoDyn, purchased leronlimab from Progenics through a licensing agreement. Links to Leronlimab specific papers https://investorshangout.com/post/view?id=5605721 CCR5/Cancer potential mechanism of actions CCR5: Enables cancer metastasis, Activates DNA mechanism, Regulates body anti-tumor response, Promotes Angiogenesis and Cancer Recurrence Paper links: https://investorshangout.com/post/view?id=5506865 https://investorshangout.com/post/view?id=5554877 CCR5 studies with all major cancer types: breast, lung, prostate, colorectal, melanoma, non-hodgkin lymphoma, kidney, leukemia, pancreatic, liver, gastic, hodgkin lymphoma, cervical https://investorshangout.com/post/view?id=5446988 https://investorshangout.com/post/view?id=5447120 Other ccr5 connections Leronlimab, CCR5 and NASH https://investorshangout.com/post/view?id=5554859 https://investorshangout.com/post/view?id=5341166 Leronlimab, CCR5 and GvHD https://investorshangout.com/post/view?id=5616457 https://investorshangout.com/post/view?id=5335577 https://investorshangout.com/post/view?id=5356864 Leronlimab, CCR5 and Atherosclerosis https://investorshangout.com/post/view?id=5554865 Leronlimab, CCR5 and Diabetes https://investorshangout.com/post/view?id=5556873 Leronlimab, CCR5 and Stroke https://investorshangout.com/post/view?id=5556876 Leronlimab, CCR5 and Inflammatory Bowel Diseases https://investorshangout.com/post/view?id=5556877 Leronlimab, CCR5 and Pulmonary Diseases https://investorshangout.com/post/view?id=5554863 Leronlimab, CCR5 and COPD, Emphysema https://investorshangout.com/post/view?id=5579736 Leronlimab, CCR5 and Tuberculosis https://investorshangout.com/post/view?id=5579740 Leronlimab, CCR5, and Hepatitis https://investorshangout.com/post/view?id=5529824 Leronlimab, CCR5, and Multiple Sclerosis, Alzheimer's, Parkinsons, blood brain barrier https://investorshangout.com/post/view?id=5455839 https://investorshangout.com/post/view?id=5611149 https://investorshangout.com/post/view?id=5614370 https://investorshangout.com/post/view?id=5616194 https://investorshangout.com/post/view?id=5614503 Extra: CTC as a possible biomarker when applying for BTD with cancer https://investorshangout.com/post/view?id=5607820 Estimating Unmet Need Population for Combo Last survey, people on HAART with CD4 count <=200 (AIDS) https://investorshangout.com/post/view?id=5335738 https://investorshangout.com/post/view?id=5335594 R5/X4 distribution/correlation with CD4 count https://www.prn.org/index.php/management/arti...opism_1002 HIV/AIDS stats: https://www.hiv.gov/hiv-basics/overview/data-...statistics FDA denied ODD for HIV Combo because HIV Mono population size > 200,000 https://www.cytodyn.com/newsroom/press-releas...v-patients Adding ccr5 inhibitor to HIV HAART to combat added risk with HIV HIV and NASH https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550355/ HIV and Cancer https://www.cancer.net/cancer-types/hivaids-r...troduction https://investorshangout.com/post/view?id=5624803 Market Size and Old Sales Models for HIV Wainwright Update July 2019 https://investorshangout.com/post/view?id=5479444 Rodman & Renshaw (unit of Wainwright) 2016 Report https://investorshangout.com/post/view?id=5623635 CYDY BioVid Study (slides showing some data) https://investorshangout.com/post/view?id=5625737 FS Model https://cdn.discordapp.com/attachments/282295...ydy-02.pdf https://cdn.discordapp.com/attachments/282295...ydy-02.ods HIV cure Discussion on Dr Sacha’s work with possibly a cure with monkeys using a variety of tools including donor cells, chemo or radiation, possibly gvhd and then leronlimab https://investorshangout.com/post/view?id=5505597 https://investorshangout.com/post/view?id=5581337 Unmet Need Drugs Appoved compared to Leronlimab Leronlimab 81% suppressed viral load after 2, MDR2 with limited options or MDR3, N=50 Maraviroc(MVC), MDR3, N=1049, 45% at 24 & 48 weeks, https://www.nejm.org/doi/full/10.1056/nejmoa0803152 Trogarzo(ibalizumab or IZ) 43% suppressed at 25 weeks, N=40, MDR3 Disadvantages of Trogarzo: biweekly IV, cost 120k per year, MDR3, side-effects (including seriuos IRIS) https://www.rxlist.com/trogarzo-side-effects-drug-center.htm Disadvantages of Maraviroc: black box warning, MDR3, has resistance within R5, daily pills, side-effects (inluding serious hepatotoxicity) -https://www.goodrx.com/maraviroc/side-effects Testimonials Charlie Sheen talking experience switching from HAART to Pro 140 in 2016 as a patient in the p3 mono investigatory trial. He has not given an update on his status since 2017. https://www.poz.com/article/ccr5blocking-anti...n/comments Maraviroc P1 trial results for with Metastatic Colorectal Cancer https://www.cell.com/cancer-cell/pdfExtended/...16)30087-3 Dolutegravir used with kids because of the high genetic barrier to resistance (link below). The FDA requested BLA part 1 to contain pediatric info and data from mono trial. https://investorshangout.com/post/view?id=5532206 Importance of Adherence https://www.ajmc.com/journals/supplement/2013...echer_s231 http://hivinsite.ucsf.edu/InSite?page=kb-03-02-09 Cenicriviroc (ccr5/ccr2 antagonist) buyout NASH for 1.7B https://www.benzinga.com/general/biotech/16/0...rug-a-key- CCR5 Antagonists in HIV trials Aplaviroc discontined trials: liver toxicity and poor efficacy http://www.thebody.com/content/art39205.html Vicriviroc was canceled phase 3 for possibly both side-effects and efficacy. Cenicriviroc after phase2b with HIV switch focus to NASH Maraviroc approved R5 HIV unmet neet and naive population PrEP and R5 transmission https://www.prn.org/index.php/management/arti...opism_1002 https://www.ncbi.nlm.nih.gov/pubmed/12815099 AGC Biologics Information https://investorshangout.com/post/postreplies?id=5617700 wiki links https://en.wikipedia.org/wiki/CCR5_receptor_antagonist https://en.wikipedia.org/wiki/CCR5 https://en.wikipedia.org/wiki/CCL5 https://en.wikipedia.org/wiki/PRO_140 [1] https://www.nature.com/articles/381667a0 [2] https://www.npr.org/sections/health-shots/201...ight-virus [3] https://www.ncbi.nlm.nih.gov/pubmed/10196311 [4] https://jvi.asm.org/content/75/2/579.short [5] https://www.ncbi.nlm.nih.gov/pubmed/12815099 [6] https://www.ajmc.com/journals/supplement/2013...echer_s231 [7] http://hivinsite.ucsf.edu/InSite?page=kb-03-02-09 [8] https://content.sciendo.com/view/journals/rao...b_body=pdf [9] https://cancerres.aacrjournals.org/content/79/19/4801 [10] https://aidsinfo.nih.gov/drugs/423/leronlimab/0/professional [11] https://www.poz.com/article/PRO140-HIV-Entry-12672-5546 [12] https://www.cytodyn.com/newsroom/press-releas...ab-pro-140 Read More: https://investorshangout.com/post/view?id=5627230#ixzz6FIAjxigQ

CYDY / Message Board / Read Message BOARD GROUPS return to message board, top of board Msg 222 of 224 at 2/28/2020 10:49:26 PM by rubraquercus In response to msg 220 by rubraquercus view thread Hi All- I wanted to share this break through stock with everyone. They have a drug called Leronlimab that is only to change the HIV and Cancer landscape IMO. Please read below. Their drug is in BTD (Biological Therapeutic Designation) for HIV, which was fast tracked through the FDA right now. The FDA granted them a basket trial for 22 different forms of tumorous cancer as of a week ago. It is being tested in China right now for the Corona Virus. Charlie Sheen the actor's testimonial is below as well. He is on the drug as well. This stock could be the opportunity of a lifetime. Please read below. Re: CYDY article Leronlimab (Pro 140) Cliff Notes What is it? Leronlimab is a humanized monoclonal antibody targeted against the CCR5 receptor expressed on sub-population of T cells, macrophages, dendritic, eosinophils, microglia, and several cancers types. Why so many indications? CCR5 is a chemokine receptor interacting with CCL3, CCL4, and CCL5 (RANTES). CCL5 has an active role in recruiting leukocytes into inflammatory sites, which leronlimab can block. CCR5 also has many other roles: [8,9] - governing DNA damage repair, - repolarization of tumor-associated macrophages, - promoting leukocytes (and metastatic cancer ccr5+ cells) trafficking to the brain, bones, liver and lungs. What makes it to stand out from than other ccr5 antagonists, HAART, and cancer drugs ? Low toxicity: Doesn't block natural activity of ccr5 including no hepatotoxicity causing many others to fail their trial safety metric. No R5 resistance: Competitive inhibitor blocking direct entry to target a specific site on CCR5 that is utilized by HIV vs allosteric in small molecule, which enables resistance development in all small molecule antagonists. With the highest barrier to resistance so far than any other HIV drug, it could be first monotherapy approved drug for HIV. Weekly dosing/Adherence : Longer half-life (10-14 days) [11,12] allows weekly dosing vs daily pills with others. A large 2013 survey [6,7] of 19 studies showed the association between adherence and specific AEs associated with ART. The same study showed an association with adherence rate and the number of daily pills, 95% adherence from 47% taking one pill daily to 34% with three pills daily. NNRTI, which has traditionally been given as part of core with ART, needs a very high level of adherence to limit mutations Adherence is the second strongest predictor of progression to AIDS after CD4 count. Weekly dosing offers a tremendous advantage in increasing adherence, specifically those in the unmet need category where typically adherence has been the lowest. Note PrEP study will have one arm with monthly dosing as daily pills is one main reason people at risk have stated they avoided PrEP, longer options are better. Safety: No serious side effects or serious adverse events in over 830 patients. No discontinuing thus far from AEs in mono p2 trial. This makes leronlimab unique among many HIV and cancer drugs. Recognizing overall's drug’s safety FDA has allowed P1 to be skipped in several new indications. This is also helps reduce the added compounding side-effects when using several drugs with HIV or cancer. Low drug/drug interactions. Leronlimab is eliminated via a saturable, antigen-mediated clearance process [10]. Many other HIV drugs are metabolized by CYP enzymes enabling drug interactions. For example Maraviroc and Rilpivirine are metabolized by CYP3A4, as are many other drugs. Special Note: HIV has a positive association with NAFLD and cancer, two indications where leronlimab is in p2, which combined with the above benefits, if approved for all indications would make a extremely compelling synergistic treatment for all R5. See end footnote for more details. Video: Pro 140: How it Combats HIV Science Advisors : Dr Sacha/OHSU, Dr. Patterson/IncellDx, Dr. Lindner/ Cleveland Clinic, Dr. Dennis Burger/ex-CSO CYDY, also CEO of several nasdaq bio, Dr. Maddon (inventor or leronlimab and discovered CD4/HIV connection) Clinical Advisors : Dr Dhody/Amarex Clinical Research, Dr Dolezal/Pacific Hematoloty, Dr. Lalezari/Quest Clinical Research Manufacturing : AGC & Samsung Biologics (mAb global leader which approved deal with no upfront payment) HIV: Combo: Unmet Need R5 Population. Fast Track Designation, Completed Phase3 with BLA submission December/January, BLA rolling review Mono: R5 Population suppressed V.: In Phase 2b/3 investigatory trial. Phase 3 pivotal could start 2020 with FDA approval, 5 patients on mono five years with no drug resistance; over 150 patients on mono for over 1 year PrEP: Coordinating with Thai Red Cross/Dr Sacha funding for 1200 patient study, one arm monthly dosing Potential partner US Army, talks with US Senators with funding, first goal BTD submission. Though an estimated 70% of HIV population is R5, over 90% of HIV sexual transmissions occur throuh the CCR5 pathway. [5] Licensing: Vyera US/HIV only, 50% net sales & 87M milestone. Other global and US non-HIV still open. FDA denied ODD stating population larger than 200k is a possibility Cancer Animal: 98% metastatic tumor burden reduction in tnbc mice model mTNBC — Fast Track Designation: Phase 1b/2: Patient 1 CTC reduced to zero in first eight weeks, matching similar results in animal model. Enrolling next two soon. Will Apply for BTD if similar results Colon —Phase 2 approval, 30 patient with Regorafenib, enrollment not started Compassionate use approved: melanoma, pancreatic, lung, liver, breast, and prostate Basket trial with in works with melanoma, pancreatic, lung, liver, breast, and prostate NASH Animal: inhibited lipid uptake, liver fibrosis, and fatty liver development Phase 2 approval, 60 patients, random, double blind-enrollment not started Brenden Rae, “ we expect there to be a significant interest from industry stakeholders in the development of leronlimab for the treatment of NASH.” GvHD : Orphan Drug Designation Animal: 100% survival with leronlimab vs 0 without Phase 2 approval 60 patient, enrollment not started Note: P2 maraviroc trial with GvHD successful Multiple Sclerosis P2 protocol already finalized by Dr. Denis Burger following same structure of Biogen's Tysabri. IND submission early 2020 History In 1994, Stephen Crohn [2] became the first person observed to have some genetic resistance to HIV, he had mutation later known as ccr5-delta-32. Ths mutation has been used to aid two 'sterilizing' cures known to date with using a high-risk delta 32 stem cell transplantation to treat life-treating leukemia and Hodgkin's lymphoma respectively for Timothy Brown original referred to as the Berlin Patient (2007) and London Patient (2019). Progenics, founded by Paul Maddon in 1986, originally developed leronlimab. Their scientist and collaborators on the original team that in 1996 discovered CCR5 is necessary as a co-receptor for entry macrophage tropic HIV in strains now called R5[1]. In 1999, from 10,000 hybridoma supernatants screened, and over 100 inhibiting ccr5, seven were selected for testing [3]. From those seven, leronlimab was selected partly due to its wide coverage in all tested R5 strains and the observation that it does not antagonize natural receptor activity [4], which gives low treatment-related toxicities compared to other ccr5 antagonist or highly-active antiretroviral therapy used in HIV. At Progenics, leronlimab, entered phase 1 in 2006 followed by two phase 2 studies in 2008, one IV and the other subcutaneous for HIV R5 strain with results published in 2010. Progenics switched focus in 2010 to other potential drugs in their pipeline, partly influenced by the FDA pathway given of leronlimab through unmet need estimated taking many years. In 2012, CytoDyn, purchased leronlimab from Progenics through a licensing agreement. Links to Leronlimab specific papers https://investorshangout.com/post/view?id=5605721 CCR5/Cancer potential mechanism of actions CCR5: Enables cancer metastasis, Activates DNA mechanism, Regulates body anti-tumor response, Promotes Angiogenesis and Cancer Recurrence Paper links: https://investorshangout.com/post/view?id=5506865 https://investorshangout.com/post/view?id=5554877 CCR5 studies with all major cancer types: breast, lung, prostate, colorectal, melanoma, non-hodgkin lymphoma, kidney, leukemia, pancreatic, liver, gastic, hodgkin lymphoma, cervical https://investorshangout.com/post/view?id=5446988 https://investorshangout.com/post/view?id=5447120 Other ccr5 connections Leronlimab, CCR5 and NASH https://investorshangout.com/post/view?id=5554859 https://investorshangout.com/post/view?id=5341166 Leronlimab, CCR5 and GvHD https://investorshangout.com/post/view?id=5616457 https://investorshangout.com/post/view?id=5335577 https://investorshangout.com/post/view?id=5356864 Leronlimab, CCR5 and Atherosclerosis https://investorshangout.com/post/view?id=5554865 Leronlimab, CCR5 and Diabetes https://investorshangout.com/post/view?id=5556873 Leronlimab, CCR5 and Stroke https://investorshangout.com/post/view?id=5556876 Leronlimab, CCR5 and Inflammatory Bowel Diseases https://investorshangout.com/post/view?id=5556877 Leronlimab, CCR5 and Pulmonary Diseases https://investorshangout.com/post/view?id=5554863 Leronlimab, CCR5 and COPD, Emphysema https://investorshangout.com/post/view?id=5579736 Leronlimab, CCR5 and Tuberculosis https://investorshangout.com/post/view?id=5579740 Leronlimab, CCR5, and Hepatitis https://investorshangout.com/post/view?id=5529824 Leronlimab, CCR5, and Multiple Sclerosis, Alzheimer's, Parkinsons, blood brain barrier https://investorshangout.com/post/view?id=5455839 https://investorshangout.com/post/view?id=5611149 https://investorshangout.com/post/view?id=5614370 https://investorshangout.com/post/view?id=5616194 https://investorshangout.com/post/view?id=5614503 Extra: CTC as a possible biomarker when applying for BTD with cancer https://investorshangout.com/post/view?id=5607820 Estimating Unmet Need Population for Combo Last survey, people on HAART with CD4 count <=200 (AIDS) https://investorshangout.com/post/view?id=5335738 https://investorshangout.com/post/view?id=5335594 R5/X4 distribution/correlation with CD4 count https://www.prn.org/index.php/management/arti...opism_1002 HIV/AIDS stats: https://www.hiv.gov/hiv-basics/overview/data-...statistics FDA denied ODD for HIV Combo because HIV Mono population size > 200,000 https://www.cytodyn.com/newsroom/press-releas...v-patients Adding ccr5 inhibitor to HIV HAART to combat added risk with HIV HIV and NASH https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550355/ HIV and Cancer https://www.cancer.net/cancer-types/hivaids-r...troduction https://investorshangout.com/post/view?id=5624803 Market Size and Old Sales Models for HIV Wainwright Update July 2019 https://investorshangout.com/post/view?id=5479444 Rodman & Renshaw (unit of Wainwright) 2016 Report https://investorshangout.com/post/view?id=5623635 CYDY BioVid Study (slides showing some data) https://investorshangout.com/post/view?id=5625737 FS Model https://cdn.discordapp.com/attachments/282295...ydy-02.pdf https://cdn.discordapp.com/attachments/282295...ydy-02.ods HIV cure Discussion on Dr Sacha’s work with possibly a cure with monkeys using a variety of tools including donor cells, chemo or radiation, possibly gvhd and then leronlimab https://investorshangout.com/post/view?id=5505597 https://investorshangout.com/post/view?id=5581337 Unmet Need Drugs Appoved compared to Leronlimab Leronlimab 81% suppressed viral load after 2, MDR2 with limited options or MDR3, N=50 Maraviroc(MVC), MDR3, N=1049, 45% at 24 & 48 weeks, https://www.nejm.org/doi/full/10.1056/nejmoa0803152 Trogarzo(ibalizumab or IZ) 43% suppressed at 25 weeks, N=40, MDR3 Disadvantages of Trogarzo: biweekly IV, cost 120k per year, MDR3, side-effects (including seriuos IRIS) https://www.rxlist.com/trogarzo-side-effects-drug-center.htm Disadvantages of Maraviroc: black box warning, MDR3, has resistance within R5, daily pills, side-effects (inluding serious hepatotoxicity) -https://www.goodrx.com/maraviroc/side-effects Testimonials Charlie Sheen talking experience switching from HAART to Pro 140 in 2016 as a patient in the p3 mono investigatory trial. He has not given an update on his status since 2017. https://www.poz.com/article/ccr5blocking-anti...n/comments Maraviroc P1 trial results for with Metastatic Colorectal Cancer https://www.cell.com/cancer-cell/pdfExtended/...16)30087-3 Dolutegravir used with kids because of the high genetic barrier to resistance (link below). The FDA requested BLA part 1 to contain pediatric info and data from mono trial. https://investorshangout.com/post/view?id=5532206 Importance of Adherence https://www.ajmc.com/journals/supplement/2013...echer_s231 http://hivinsite.ucsf.edu/InSite?page=kb-03-02-09 Cenicriviroc (ccr5/ccr2 antagonist) buyout NASH for 1.7B https://www.benzinga.com/general/biotech/16/0...rug-a-key- CCR5 Antagonists in HIV trials Aplaviroc discontined trials: liver toxicity and poor efficacy http://www.thebody.com/content/art39205.html Vicriviroc was canceled phase 3 for possibly both side-effects and efficacy. Cenicriviroc after phase2b with HIV switch focus to NASH Maraviroc approved R5 HIV unmet neet and naive population PrEP and R5 transmission https://www.prn.org/index.php/management/arti...opism_1002 https://www.ncbi.nlm.nih.gov/pubmed/12815099 AGC Biologics Information https://investorshangout.com/post/postreplies?id=5617700 wiki links https://en.wikipedia.org/wiki/CCR5_receptor_antagonist https://en.wikipedia.org/wiki/CCR5 https://en.wikipedia.org/wiki/CCL5 https://en.wikipedia.org/wiki/PRO_140 [1] https://www.nature.com/articles/381667a0 [2] https://www.npr.org/sections/health-shots/201...ight-virus [3] https://www.ncbi.nlm.nih.gov/pubmed/10196311 [4] https://jvi.asm.org/content/75/2/579.short [5] https://www.ncbi.nlm.nih.gov/pubmed/12815099 [6] https://www.ajmc.com/journals/supplement/2013...echer_s231 [7] http://hivinsite.ucsf.edu/InSite?page=kb-03-02-09 [8] https://content.sciendo.com/view/journals/rao...b_body=pdf [9] https://cancerres.aacrjournals.org/content/79/19/4801 [10] https://aidsinfo.nih.gov/drugs/423/leronlimab/0/professional [11] https://www.poz.com/article/PRO140-HIV-Entry-12672-5546 [12] https://www.cytodyn.com/newsroom/press-releas...ab-pro-140 Read More: https://investorshangout.com/post/view?id=5627230#ixzz6FIAjxigQ

Thanks Adam! We appreciate all the hard work and everything you have done! Can’t wait for this ride to be over after 12 years!

Thanks Adam, I can’t wait for this RV to happen!

Thanks Adams! This is awesome news! Go hcl and go RV

This to me is not a good thing. The rate is going in the wrong direction. We want it to get closer to one not go farther away😀

I would take any move to the upside after waiting 10 years !!!

Thanks, Adam for all that you do!!! Sounds pretty promising

In my portfolio I own BX (Blackstone) 6% yield and EPD (Oil/Gas Pipeline MLP) 6% yield. Good luck in your research!

I am definitely getting excited again!!!! Thanks for the update:)

Thanks Adam!!

Thanks Yota and K98 on the updates!!!

I agree with everything you said:) I feel better now!!

My family will definitely be praying for Rob's dad!!!

Thank you Adam for everything!!! Look forward to meeting you one day:)

That for the chat Adam!!! It's seems like this could come to a closure soon. GOOOO RVVVV!!!

Hi Irock- This happen once a year. Every year you will need to submit an authorization form to Warka bank, which your can send to Mr. Issa, for the deduction of 15,000 IQD from the use of an online banking account. I hope this helps:)

Thanks for the info Scooter!! I look forward to hearing what you have to say:)

I have purchased from GID Assoicates. I think they are the cheapest and the service is great also:)

Thanks for the heads up, I went after reading your post and noticed that my account now is up dated!!!!!!!

Thanks, I appreciate it

I can't lie, I am worried about it myself

I hope so:)

Hi All- I logged in under my account of which I have done many many times and clicked on Display account and nothing showed up. Normally it would show you your balance. I know two others as well which this happened to. Does anyone know why this is happening. Adam can you please comment if possible? Thanks

It is 21.3 billion that they are writing off. In 2008 they wrote of 7 billion.